Serafin Labs, Inc.

Serafin Labs is a therapeutics company advancing a novel class of anti-metastatic cancer therapies that stops the spread of cancer in the body and targets drug resistance. Their targets are identified using a platform that encourages cancer organoids to enter metastatic phenotypes at scale across multiple cancers. This approach has led to discovery of a lead candidate, SERA-01, for pancreatic and triple-negative breast cancer. Relevance to Patients: Serafin Labs is developing therapies that prevent cancer from spreading and resist treatment failure. Its platform identifies drugs that traditional methods cannot, delivering safer and more effective treatment options for patients with aggressive cancers.